Q/C Technologies Q3 Loss Narrows to $0.9M; Discloses 4.98M-Share Warrant Exchange at $0.3101
QCLS is trading near its 52-week low of $0.301 (0.6% above the low).
Summary
Q/C Technologies posted a $0.9M Q3 net loss (flattered by a $1.5M non-cash derivative gain) and disclosed a November 15 related-party warrant exchange that issues 4,982,272 shares at $0.3101 and resets preferred conversion and warrant prices to that level.
Key Events · Earnings and Guidance · QCLS
-
Q3 Loss Narrows on Non-Cash Gain
Net loss was $941,793 versus $2,811,388 a year earlier, but the swing came from a $1,541,000 non-cash gain on remeasuring the Series H derivative liability — not operations.
-
Nine-Month Loss Widens to $11.3M
The nine-month net loss was $11,313,780 versus $5,732,326, including a $3,177,999 impairment of the terminated LightSolver technology license.
-
Related-Party Warrant Exchange Dilutes
On November 15, 2026 PharmaCyte exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares at $0.3101, and anti-dilution provisions reset Series G and Series H conversion prices and certain warrant strikes to $0.3101.
-
Liquidity Claimed for Twelve Months
Cash of $2,585,051 plus $6,805,270 of marketable securities at September 30, 2026; management says resources fund operations for at least twelve months.
Analysis · QCLS · Life Sciences
The quarter looks better than a year ago — a $941,793 net loss versus $2,811,388 — but that improvement is almost entirely a $1,541,000 non-cash gain from remeasuring the Series H derivative liability as the share price fell, not an operating gain. The nine-month picture is worse: an $11.3M net loss that includes a $3.18M write-off of the terminated LightSolver license. More consequential is the November 15 warrant exchange with PharmaCyte, a related party whose interim CEO is Q/C's own Executive Chairman. PharmaCyte swapped 851,304 Series G warrants for 4,982,272 new shares priced at $0.3101 — roughly 58% of the 8.62M shares outstanding — and the anti-dilution ratchets reset the Series G and Series H conversion prices and certain warrant strikes to that same $0.3101. That is real, large dilution layered on top of a stock already trading near its 52-week low and under a Nasdaq bid-price deficiency notice with a May 5, 2027 cure deadline.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QCLS was trading at $0.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $0.30 to $8.17. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.